Xiangbin Tan*1, Zefei Liao†1, Shuangyou Zou*, Liangyun Ma†, Aimin Wang*
Oncology Research, Vol.28, No.1, pp. 3-11, 2020, DOI:10.3727/096504019X15509383469698
Abstract Vasohibin2 (VASH2), a proangiogenic factor, has been demonstrated to play an oncogenic role in some
common human cancers. However, the detailed function of VASH2 in non-small cell lung cancer (NSCLC) has
not previously been studied. In this study, we found that VASH2 was significantly upregulated in NSCLC tissues
and cell lines, and its increased expression was associated with NSCLC progression and poor prognosis of
patients. Knockdown of VASH2 markedly inhibited cell proliferation and P-glycoprotein expression in NSCLC
cells. Overexpression of VASH2 enhanced cell proliferation, P-glycoprotein expression, as well as doxorubicin
resistance in NSCLC cells. Moreover,… More >